Literature DB >> 20459883

Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.

W Wolfgang Fleischhacker1, Martti E Heikkinen, Jean-Pierre Olié, Wally Landsberg, Patricia Dewaele, Robert D McQuade, Jean-Yves Loze, Delphine Hennicken, Wendy Kerselaers.   

Abstract

Clozapine is associated with significant weight gain and metabolic disturbances. This multicentre, randomized study comprised a double-blind, placebo-controlled treatment phase of 16 wk, and an open-label extension phase of 12 wk. Outpatients who met DSM-IV-TR criteria for schizophrenia, who were not optimally controlled while on stable dosage of clozapine for > or =3 months and had experienced weight gain of > or =2.5 kg while taking clozapine, were randomized (n=207) to aripiprazole at 5-15 mg/d or placebo, in addition to a stable dose of clozapine. The primary endpoint was mean change from baseline in body weight at week 16 (last observation carried forward). Secondary endpoints included clinical efficacy, body mass index (BMI) and waist circumference. A statistically significant difference in weight loss was reported for aripiprazole vs. placebo (-2.53 kg vs. -0.38 kg, respectively, difference=-2.15 kg, p<0.001). Aripiprazole-treated patients also showed BMI (median reduction 0.8 kg/m(2)) and waist circumference reduction (median reduction 2.0 cm) vs. placebo (no change in either parameter, p<0.001 and p=0.001, respectively). Aripiprazole-treated patients had significantly greater reductions in total and low-density lipoprotein (LDL) cholesterol. There were no significant differences in Positive and Negative Syndrome Scale total score changes between groups but Clinical Global Impression Improvement and Investigator's Assessment Questionnaire scores favoured aripiprazole over placebo. Safety and tolerability were generally comparable between groups. Combining aripiprazole and clozapine resulted in significant weight, BMI and fasting cholesterol benefits to patients suboptimally treated with clozapine. Improvements may reduce metabolic risk factors associated with clozapine treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20459883     DOI: 10.1017/S1461145710000490

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  48 in total

Review 1.  Is rational antipsychotic polytherapy feasible? A selective review.

Authors:  Rune Andreas Kroken; Erik Johnsen
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

2.  Polypharmacy of schizophrenia.

Authors:  Peter Dussias; Amir H Kalali; Leslie Citrome
Journal:  Psychiatry (Edgmont)       Date:  2010-08

3.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

4.  Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom.

Authors:  Amanda J Wheeler; Celia L Feetam; Jeff Harrison
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

Review 5.  The interface of physical and mental health.

Authors:  Anne M Doherty; Fiona Gaughran
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-02-22       Impact factor: 4.328

6.  Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme.

Authors:  Shubhra Mace; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2015-02

Review 7.  Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria.

Authors:  Robin Murray; Christoph U Correll; Gavin P Reynolds; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2017-03-01

8.  Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.

Authors:  Britta Galling; Alexandra Roldán; Katsuhiko Hagi; Liz Rietschel; Frozan Walyzada; Wei Zheng; Xiao-Lan Cao; Yu-Tao Xiang; Mathias Zink; John M Kane; Jimmi Nielsen; Stefan Leucht; Christoph U Correll
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

9.  Combination and high-dose atypical antipsychotic therapy in patients with schizophrenia: systematic review.

Authors: 
Journal:  CADTH Technol Overv       Date:  2012-09-01

Review 10.  Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.

Authors:  Yuya Mizuno; Takefumi Suzuki; Atsuo Nakagawa; Kazunari Yoshida; Masaru Mimura; Walter Wolfgang Fleischhacker; Hiroyuki Uchida
Journal:  Schizophr Bull       Date:  2014-03-17       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.